Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain.